Feasibility and preliminary outcomes of a remotely-delivered exercise training intervention for English-speaking Hispanics/Latinos with multiple sclerosis: Results from the FERLA MS study
Multiple Sclerosis Journal - Experimental, Translational and Clinical · Published 2026-04-01 · DOI 10.1177/20552173261448001
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/20552173261448001
Abstract
Background There is limited evidence on the feasibility of remotely delivered exercise interventions for English-speaking Hispanics/Latinos with MS. Objectives To evaluate the feasibility and exploratory efficacy of a remotely-delivered, home-based exercise program for English-speaking Hispanics/Latinos with MS and to explore associations among feasibility metrics, outcomes, and social determinants of health (SDOH). Results Of 340 individuals contacted, 112 were eligible (33%), 33 enrolled (9.7%), 30 randomized, and 26 completed (87% retention). Adherence averaged 81% (exercise) and 89% (control). No serious adverse events occurred. Exploratory within-group improvements were observed in the exercise group for physical activity ( p = 0.03, d = 0.66). Mobility improved by 10.1 points on the MS Walking Scale–12, exceeding the minimal clinically important difference. Exploratory analyses indicated that higher education correlated with greater program compliance ( ρ =0.70, p = 0.005) and lower anxiety ( ρ =-0.69, p = 0.006). Conclusions Our results support the feasibility, safety, and preliminary benefits of remotely-delivered, home-based exercise training for improvements in physical activity and mobility for English-speaking Hispanics/Latinos with MS. Exploratory results warrant evaluation in larger, adequately powered trials. Clinical Trial Registration ClinicalTrials.gov (NCT05998616).
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2026
Related articles
- Comorbidities in newly diagnosed multiple sclerosis patients: A population-based register study in Finland · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Real-world safety and effectiveness of ofatumumab in multiple sclerosis: A clinic-based study in Australia · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Men's health research priorities in men with multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Music therapy with a monochord in multiple sclerosis (“MUTIMS”): A randomized, controlled, rater-blinded trial · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Deep cervical lymph node volume decreases following B-cell depletion therapy · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal
- Establishing demographic-based normative values for neurofilament light chain and glial fibrillary acidic protein in serum and plasma samples · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and pain · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2026 · Same journal
- Analysis of an innovative fluid biomarker panel for early prediction of progression independent of relapse activity in multiple sclerosis · Multiple Sclerosis Journal - Experimental, Translational and Clinical · 2025 · Same journal